71183 | NucBuster™ Protein Extraction Kit

Price could not be retrieved
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited Availability Limited Availability
Limited Quantities Available
Availability to be confirmed
      Will advise
      View Pricing & Availability
         CompareClick To Print This Page


      Pricing & Availability

      Catalogue NumberAvailability Packaging Qty/Pack Price Quantity
      Retrieving availability...
      Limited Availability Limited Availability
      Limited Quantities Available
      Availability to be confirmed
          Will advise

          100 rxns
          Retrieving price...
          Price could not be retrieved
          Upon Order Completion More Information
          You Saved ()
          Request Pricing
          Overview The NucBuster™ Protein Extraction Kit (Bruggink 2002) provides an alternative to the time intensive and cumbersome traditional methods for preparing nuclear extracts from mammalian cells. Time consuming traditional methods (up to 7 hours), based on a procedure originally described by Dignam et al. (1983), includes suspending cells in hypotonic solution, Dounce homogenization, centrifugation, and dialysis. The NucBuster Kit protocol is rapid and allows for the easy processing of multiple samples. The entire procedure from start to finish yields ready-to-use nuclear extract within 30 minutes. The composition of gentle detergents and salt in the final NucBuster extract is directly compatible with electrophoretic mobility shift assays (EMSA).

          The NucBuster protocol is based on two proprietary detergent-based solutions, NucBuster Extraction Reagent 1, optimized for cell lysis and removal of cytoplasmic components, and NucBusterExtraction Reagent 2, optimized for extraction of nuclear proteins. In addition, NucBuster extract is free of the 'stickiness' associated with release of genomic DNA, a problem associated with some traditional methods. No Dounce homogenization is required and there is no need for dialysis. The entire procedure is performed in a single microcentrifuge tube and requires only a vortex mixer and microcentrifuge. The kit provides enough reagents for 100 preparations of nuclear extract from 1 x 107 to 5 x 107 cells and the protocol is scalable.

          Catalogue Number 71183
          Brand Family Novagen®
          Features and benefits
          • Nuclear extract preparation in 30 minutes
          • No homogenization or dialysis required
          • Procedure performed in a single microcentrifuge tube
          • Extracts suitable for activity assays, electrophoretic mobility shift assays (EMSA), and NoShift™ Transcription Factor Assays
          References Bruggink, F. and Hayes, S. 2002. inNovations 15, 9.
          Dignam, J.D., et al. 1983. Nucl. Acids Res. 11, 1475.
          Product Information
          2 × 7.5 mlNucBuster Extraction Reagent 1
          7.5 mlNucBuster Extraction Reagent 2
          100 µl100 mM DTT
          1 setProtease Inhibitor Cocktail Set I (lyophilized, makes 100 µl)
          Biological Information
          Physicochemical Information
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped with Blue Ice or with Dry Ice
          Toxicity Multiple Toxicity Values, refer to MSDS
          Storage -20°C
          Do not freeze No
          Packaging Information
          Transport Information
          Supplemental Information



          Danmark Deutschland Ellas
          English España France
          Italia Korea Magyarország
          Nederland  Norge Polska
          Portugal Suomi Sverige

          Certificates of Analysis

          TitleLot Number


          Reference overview
          Bruggink, F. and Hayes, S. 2002. inNovations 15, 9.
          Dignam, J.D., et al. 1983. Nucl. Acids Res. 11, 1475.


        • Di Ai, et al. (2007) Nuclear factor 1 and T-cell factor/LEF recognition elements regulate Pitx2 transcription in pituitary development. Molecular and Cellular Biology 27, 5765-5775.
        • Maria Nikodemova, et al. (2007) Minocycline Down-regulates MHC II Expression in Microglia and Macrophages through Inhibition of IRF-1 and Protein Kinase C (PKC)/II. Journal of Biological Chemistry 282, 15208-15216.
        • Jason Partridge, et al. (2007) Laminar shear stress acts as a switch to regulate divergent functions of NF-B in endothelial cells. Federation of American Societies for Experimental Biology Journal 21, 3553-3561.
        • Olga Pekar, et al. (2007) p53 regulates cyclophosphamide teratogenesis by controlling caspases 3, 8, 9 activation and NF-B DNA binding. Reproduction 134, 379-388.
        • D. Puppala, C.G. Gairola and H.I. Swanson. (2007) Identification of kaempferol as an inhibitor of cigarette smoke-induced activation of the aryl hydrocarbon receptor and cell transformation. Carcinogenesis 28, 639-647.
        • Markus Bredel, et al. (2006) Tumor necrosis factor-α-induced protein 3 as a putative regulator of nuclear factor-κB-mediated resistance to O6-alkylating agents in human glioblastomas. Journal of Clinical Oncology 24, 274-287.
        • Ying Zhang, Mingjuan Liao and Maria L. Dufau. (2006) Phosphatidylinositol 3-kinase/protein kinase Cγ-induced phosphorylation of Sp1 and p107 repressor release have a critical role in histone deacetylase inhibitor-mediated depression of transcription of the luteinizing hormone receptor gene. Molecular and Cellular Biology 26, 6748-6761.
        • Susan M. Gordon, Noa Alon and Manuel Buchwald. (2005) FANCC, FANCE and FANCD2 form a ternary complex essential to the integrity of the Fanconi anemia DNA damage response pathway. Journal of Biological Chemistry 280, 36118-36125.
        • Yong Kim, et al. (2005) Mutation of cys105 inhibits dimerization of p12CDK2-AP1 and its growth suppressor effect. Journal of Biological Chemistry 280, 23273-23279.
        • Sridhar Mani, et al. (2005) Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents. Clinical Cancer Research 11, 6359-6369.
        • U. Panchapakesan, et al. (2005) PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. American Journal of Physiology: Renal 289, F1153-F1158.
        • Zachary T. Resch, et al. (2005) Stress-activated signaling pathways mediate the stimulation of pregnancy-associated plasma protein-A expression in cultured human fibroblasts. Endocrinology 147, 885-890.
        • Myriam Schaefer, et al. (2005) The transcription factors AP-1 and Ets are regulators of C3a receptor expression. Journal of Biological Chemistry 280, 42113-42123.
        • Ram N. Trivedi, et al. (2005) The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Research 65, 6394-6400.
        • Qi Wu, et al. (2005) Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells. European Molecular Biology Organization Reports 6, 551-557.
        • Jong In Yook, et al. (2005) Wnt-dependent regulation of the E-cadherin repressor snail. Journal of Biological Chemistry 280, 11740-11748.
        • Huie Jing, Jui-Hung Yen and Doina Ganea. (2004) A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2. Journal of Biological Chemistry 279, 55176-55186.
        • Maoxiang Li, et al. (2003) The phosphatase MKP1 Is a transcriptional target of p53 involved in cell cycle regulation. Journal of Biological Chemistry 278, 41059-41068.
        • User Protocols

          TB338 NucBuster™ Extraction Reagent